Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma.

Oncotarget · 2016 · PMC5342567 · PMID 27655696

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Figure 4J demonstrates that pre-treatment with proTAME resulted in a highly significant reduction in viability for all three drugs compared to single agents, and the simultaneous combination of proTAME with doxorubicin and vincristine demonstrated a significant benefit in primary cells.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.